跳至主要内容
临床试验/NCT01704547
NCT01704547已完成不适用

Geometric Reproducibility of the Lumpectomy Cavity Using a Breast Cup Immobilization Device II

University of Maryland, Baltimore1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2012年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
1
主要终点
Breast Cup Immobilization Device II (GCC 1047) Feasibility

研究概览

简要总结

The study is designed to assess the accuracy of patient breast reproducibly using the revised BCID. This study would provide data for target verification and quality assurance to eventually allow treatment of breast cancer patients for either a TBB or accelerated partial breast irradiation. The BCID is a low-risk device similar to immobilization devices used routinely in radiotherapy for other disease sites.

详细描述

Breast conserving therapy (BCT) has become the standard of care for treating early-stage breast cancers based on six prospective randomized trials with 20 years of follow-up data (Fisher). During lumpectomy, the surgeon removes the tumor and a surrounding rim of normal tissue (margin), leaving surgical clips to help designate the resection bed. Radiation treatment is directed at the whole breast for 5 1/2 weeks and is generally followed by a 1-2 week boost directed at the lumpectomy site plus a margin of normal breast tissue. The benefit of adding the tumor bed boost, (TBB) has been shown in two studies to decrease local failures [Romestaig; Bartelink].

Studies have evaluated the role of radiation following lumpectomy in very select groups which have not been able to define a group who do not benefit from the addition of radiotherapy. In the group of patients who received surgery alone, 85% of the breast recurrences occurred in the tumor bed. Due to these two facts, radiotherapy directed only at the tumor bed has been evaluated. Treating this smaller tumor volume has allowed higher doses of radiation to be delivered safely shortening the treatment course from 6-7 weeks to one week.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • The patient must consent to be in the study and have signed an IRB-approved consent form.
  • The patient must have a diagnosis of invasive or non-invasive breast cancer.
  • The patient must be planned for or have already had breast conservation surgery (i.e. lumpectomy).
  • There are at least two metal clips in the surgical cavity placed at the time of surgery for guiding the radiation oncologist in delineating the target of irradiation; or one radiographic clip placed at the time of stereotactic core needle biopsy with the intact tumor.
  • Patients who have already been treated by radiation therapy and are being seen in follow-up can also participate

排除标准

  • Male gender
  • Patients who cannot be set up comfortably in the prone position (e.g. physical disability)
  • Tumor/lumpectomy site located in a portion of the breast that cannot be visualized easily on the CT scan (e.g. superior portion of the upper outer quadrant).
  • Mastectomy was or is the recommended surgical approach.

结局指标

主要结局

Breast Cup Immobilization Device II (GCC 1047) Feasibility

时间窗: One year

Complete clinical feasibility of using a breast cup immobilization device for prone breast irradiation in terms of both geometric and dosimetric accuracy. Measurements were able to be completed on 25 participants through treatment planning CT scans.

次要结局

  • Number of Participants That Were Favorable Candidates for Receiving GammaPod Treatment(1 year)
  • Breast Cup Immobilization Device II (GCC 1047) Comfort(One year)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Department of Radiation Oncology

Principal Investigator

University of Maryland, Baltimore

研究点 (1)

Loading locations...

相似试验